Wire · opportunities
FDA greenlights ViiV's Tivicay PD for HIV-positive newborns in first month of life
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 August 2026 · Fusion42 review
The FDA has approved ViiV Healthcare’s Tivicay PD (dolutegravir) for treating HIV-1 in newborns weighing at least 2 kg, expanding access to antiretroviral therapy for this vulnerable population. This expanded indication removes previous age and weight restrictions, based on supportive clinical trial data and pharmacokinetic modelling.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 26 Aug 2026 and 3 Sep 2026.
◆ ◆ The Wire takeaway
You must prepare to support HIV treatment protocols for newborns now authorised to receive Tivicay PD, opening a rare neonatal market segment for integrase inhibitors. This approval shifts early treatment standards and creates demand for tailored paediatric HIV therapies you can supply.
◆ Coverage
4 sources · first reported 26 Aug 2026 · latest 3 Sep 2026
◆ Related on Wire
◆ Topics